Bremelanotide (PT-141) 10 mg

POPULAR 2026 | RESEARCH LIBRARY

Bremelanotide acetate (PT-141)

An evidence-based, plain-language information page on this melanocortin-receptor agonist, its narrow approved use, emerging research, safety and South African context.

Contents

What bremelanotide acetate is

Important information and disclaimer

Approved and researched uses

Potential future uses

How it works

What evidence has found

South African regulatory context

How it compares

Risks and uncertainties

Treatment and measurement safeguards

Common questions

Join for updates

Sources

Important information and disclaimer

This page is for general education. Bremelanotide is a prescription medicine where authorised and must be selected, prescribed and monitored by an appropriately qualified healthcare professional. It does not diagnose a sexual-interest disorder, recommend treatment, replace professional information, or provide personal injection or dosing instructions.

A vial labelled ‘PT-141’, ‘bremelanotide’, ‘melanocortin peptide’, ‘research grade’ or with a CAS number is not thereby equivalent to an authorised finished medicine. Identity, cyclic structure, salt content, peptide content, purity, sterility, formulation, stability and cold-chain history may be unknown.

Bremelanotide is not a universal libido enhancer or performance drug. It is contraindicated in uncontrolled hypertension or known cardiovascular disease under the US label. Chest pain, severe headache, neurological symptoms, collapse, persistent vomiting or a serious allergic reaction requires urgent medical assessment.

What is bremelanotide acetate?

Bremelanotide is a synthetic cyclic heptapeptide related to alpha-melanocyte-stimulating hormone. It is a melanocortin-receptor agonist with greatest relevance to MC4R-mediated central nervous-system pathways involved in sexual motivation and arousal. It is not a sex hormone, phosphodiesterase-5 inhibitor or growth-hormone peptide.

Identity distinctions that prevent confusion

What is bremelanotide approved or researched for?

The FDA indication is limited to premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD) characterised by low desire causing marked distress or interpersonal difficulty. The low desire must not be due to a co-existing medical or psychiatric condition, relationship problems, or the effects of a medicine or other drug.

Acquired: developed after a period of previously satisfactory sexual function

Generalised: occurs across stimulation, situations and partners rather than only in a narrow context

Clinically distressing: low desire alone is not a disorder unless it causes meaningful distress or difficulty

The US label says it is not indicated for postmenopausal women or men, and is not intended to enhance sexual performance. Diagnosis requires a sensitive assessment of health, mood, relationship context, medicines, pain, trauma, hormones and personal goals.

Other potential uses—only if future research confirms them

Bremelanotide has been studied experimentally for male erectile or sexual dysfunction and other arousal disorders. Those findings do not establish an approved treatment for men, postmenopausal women, medication-induced dysfunction or people without HSDD.

Future research may clarify responder characteristics, longer-term safety, use across more diverse populations and how central melanocortin signalling interacts with hormonal, psychological and relationship factors. It should not be presented as a treatment for infertility, depression, menopause or relationship difficulties.

How does bremelanotide work?

Central melanocortin signalling

Bremelanotide activates melanocortin receptors in the brain, particularly pathways associated with MC4R. These pathways influence sexual motivation and arousal independently of a direct sex-hormone replacement effect. The precise mechanism by which it improves HSDD symptoms is not fully established.

Desire is not the same as genital blood flow

A central desire signal differs from the peripheral vascular mechanism of PDE5 inhibitors. Sexual wellbeing remains influenced by pain, mood, safety, relationship quality, hormones, medicines, fatigue and other health conditions; one receptor pathway cannot replace a full assessment.

Transient cardiovascular effects

Bremelanotide can temporarily increase blood pressure and reduce heart rate after administration. These changes usually peak early and return toward baseline, but they are important enough to restrict use in people with uncontrolled hypertension or known cardiovascular disease.

What has evidence found?

RECONNECT phase 3 trials

Two similar randomised, double-blind, placebo-controlled phase 3 trials studied 1,267 premenopausal women with HSDD over 24 weeks. Bremelanotide produced statistically significant average improvements in validated sexual-desire scores and reductions in distress related to low desire versus placebo.

What the trials did not show

The integrated analysis did not find a significant difference in the percentage of satisfying sexual events associated with study drug within the evaluated window. This matters: improvement in desire or distress scores should not be translated into a guarantee of intercourse, orgasm, relationship improvement or a satisfying encounter.

Tolerability and discontinuation

Nausea was the most frequent adverse effect and was sometimes severe; flushing, headache, vomiting and injection-site reactions were also common. A meaningful proportion of participants discontinued because of adverse events, so average efficacy results must be considered alongside individual tolerability.

Evidence and regulatory position in 2026

Current South African context

A review of publicly accessible SAHPRA materials did not identify a South African bremelanotide or VYLEESI professional-information record on which to base a claim of local registration. This is not proof that no application, named-patient access route or later registration exists. Current status should be verified through SAHPRA and a South African pharmacist.

FDA approval does not automatically confer South African registration, lawful advertising status, supply authorisation or reimbursement. Online “PT-141” powder or nasal products should not be represented as the FDA-authorised single-dose injectable product or assumed to share its evidence and quality controls.

How bremelanotide compares with other approaches

Known risks, contraindications and uncertainties

Common adverse reactions include nausea, flushing, injection-site reactions, headache and vomiting. Nausea may require antiemetic treatment in some patients. Blood-pressure elevation and heart-rate reduction occur transiently after each use.

Do not use with uncontrolled hypertension or known cardiovascular disease under the US prescribing information.

Consider overall cardiovascular risk before treatment; repeated transient blood-pressure increases may be problematic.

Focal hyperpigmentation—including face, gums and breasts—can occur and may not fully resolve; risk rises with darker skin and repeated exposure.

Bremelanotide can slow gastric emptying and may reduce the rate or extent of absorption of oral medicines.

It can significantly reduce oral naltrexone exposure; avoid the combination when naltrexone is used to treat alcohol or opioid dependence.

Pregnancy exposure should be avoided; the label advises effective contraception and stopping treatment if pregnancy is suspected.

Safety and efficacy are not established in men, postmenopausal women, children or people using unregulated routes and formulations.

Treatment and measurement safeguards

This page deliberately does not provide a personal dose, injection timing, frequency, reconstitution instruction, syringe-unit conversion or nasal protocol. The authorised product is a defined single-dose autoinjector. Bulk powder and compounded nasal products are not interchangeable with that presentation.

Professional review should confirm the HSDD definition, exclude contributing health or medicine causes, assess blood pressure and cardiovascular risk, review pregnancy potential and oral-drug interactions, and monitor tolerability and pigmentation. The US label includes stopping rules for lack of improvement and limits on frequency of use; the current local or imported product information must govern.

Common questions

Is PT-141 the same as bremelanotide?

PT-141 is a development name for bremelanotide, but a product bearing that label is not automatically the authorised medicine.

Is it a female Viagra?

That nickname is misleading. Bremelanotide acts centrally on melanocortin pathways; PDE5 inhibitors primarily affect genital blood flow.

Is it approved for every woman with low libido?

No. The US indication is limited to acquired, generalised HSDD in premenopausal women after other causes are excluded.

Can men use it for erectile dysfunction?

It has been researched in men, but male use is not included in the US VYLEESI indication.

Can it permanently darken the skin?

Focal pigmentation can occur and may not completely resolve, particularly with repeated exposure.

Does a CAS number prove authenticity?

No. It does not establish correct cyclic structure, peptide content, purity, sterility, formulation, stability or medicine approval.

Is it registered in South Africa?

No public SAHPRA product record was identified in this review; verify directly because regulatory records can change.

Join for research and regulatory updates

Join the future research bulletin for major evidence updates, product-information revisions, safety communications and South African status changes. Subscription does not provide medical advice, prescribing, product supply or injection instructions.

Consent wording for the future form: “I agree to receive evidence and regulatory updates by email. This service does not provide medical advice, personal dosing instructions or product supply.”

Sources and further reading

US Food and Drug Administration. VYLEESI (bremelanotide injection) prescribing information. NDA 210557; initial approval 2019.

Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134:899-908. PMID 31599840; NCT02333071 and NCT02338960.

Clayton AH, et al. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Expert Opinion on Pharmacotherapy. 2020. PMID 31893927.

ClinicalTrials.gov. RECONNECT studies NCT02333071 and NCT02338960; bridging study NCT04943068.

PubChem. Bremelanotide and bremelanotide acetate compound records.

SAHPRA. Registered health products and professional-information resources; searched 7 September 2026.

Editorial method: current regulator documents and peer-reviewed randomised evidence were prioritised over commercial pages. Product status is jurisdiction- and brand-specific. Review after major safety or registration changes, and no later than March 2027.